Clinical Research Directory
Browse clinical research sites, groups, and studies.
Psilocybin in Depression Resistant to Standard Treatments
Sponsor: King's College London
Summary
A single centre clinical trial to evaluate the feasibility, safety and efficacy of psilocybin, given under supportive conditions, in a randomised, blinded design in adult participants with treatment resistant major depressive disorder. The primary objective is to evaluate feasibility by measuring recruitment rates, dropout rates and by estimating the variance of the primary outcome measure (MADRS).
Official title: A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study
Key Details
Gender
All
Age Range
25 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2021-06-21
Completion Date
2024-12-18
Last Updated
2026-08-28
Healthy Volunteers
No
Conditions
Interventions
Psilocybin assisted therapy
A package of psychological therapy and a single dosing session of psilocybin.
Placebo assisted therapy
A package of psychological therapy and a single dosing session of placebo.
Locations (1)
Clinical Research Facility, King's College Hospital
London, London, United Kingdom